Contact Supplier

Contact Supplier

To get in touch with TAmiRNA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    .

    TAmiRNA partners with BioCat to open up new international markets

    news-releasesTAmiRNA GmbH
    May 11th 2022

    Vienna, Austria: Biotech and diagnostic innovator TAmiRNA has signed a distribution agreement with Heidelberg-based innovative life sciences research supplier BioCat GmbH that covers TAmiRNA products and CRO services.

    BioCat, located in the Heidelberg Technology Park in close proximity to the German Cancer Research Center, offers a wide range of high-quality research reagents and instruments as well as cutting-edge technologies in the fields of genomics, proteomics and cell biology fueling science in academia as well as in pharma & biotech industry.

    Opening new markets

    The distribution agreement will enable clients to get faster access to TAmiRNA products and services via the BioCat network. This will open up new markets for TAmiRNA in countries, where it has not yet been active and strengthen its reach in Germany, Switzerland and Austria.

    The partnership will include TAmiRNA’s recently developed miND® microRNA Next-Generation-Sequencing Discovery Assay pipeline that offers an innovative workflow for absolute quantification of microRNAs (miRNAs) and small RNAs in any biological sample or species, including extracellular vesicles/exosomes. The technology is based on TAmiRNA’s novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. This technology will soon become available to the small RNA research community as a stand-alone product called miND® spike-ins.

    Win-win collaboration

    TAmiRNA co-founder and CEO, Dr. Matthias Hackl, commented: “We are very pleased to be working in partnership with BioCat, which is one of the most innovative and highly respected suppliers of high quality research materials and services to the life sciences community in Europe.”

    Dr. Sieke Schaepe, Head of Inside Sales and Product Management at BioCat GmbH, added: “We are delighted to be able to add TAmiRNA’s highly innovative and distinctive offerings to our portfolio. This strengthens our own range of offerings and allows TAmiRNA to reach new research communities internationally, making this agreement a real win-win for both partners.”

    About TAmiRNA GmbH

    TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.

    For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898 and from TransBioLine project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

    More information available at: www.tamirna.com

    About BioCat GmbH

    BioCat GmbH, located in the Heidelberg Technology Park in close proximity to the German Cancer Research Center, is a privately held company founded in 2000 to market innovative products and services for life science research.

    BioCat offers a wide range of high-quality research reagents and instruments as well as cutting-edge technologies in the fields of genomics, proteomics and cell biology fueling science in academia as well as in pharma & biotech industry. It is committed to research and development to supply products with superior performance providing accurate, reliable and fast results.

    These products and services have been developed by BioCat’s network of partners in the USA, Canada, and Europe.

    BioCat supports its portfolio with expert advice from its team of Ph.D.-level scientists with in-depth backgrounds in different life sciences disciplines to help customers with questions about techniques and applications.

    Learn more at: https://www.biocat.com

    Resources

    Click on TAmiRNA NGS Data (miND®) pipeline to view video.

    TAmiRNA partners with BioCat to open up new international markets

    Contact TAmiRNA GmbH

    Simply fill out the form below to contact TAmiRNA GmbH now.

    Send TAmiRNA GmbH a Message